Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Lord Markham on 2 February (HL4910), when the next Therapeutics Clinical Review Panel is scheduled to meet to consider more recent evidence on COVID-19 risk; and who are the members of that panel.

The Therapeutics Clinical Review Panel (TCRP) met on 31 January to review new evidence on the definition and revision of eligible cohorts from COVID-19 therapeutics. There was further correspondence was conducted between the Chair and membership, and a meeting on 2 February between the Chair and Antivirals and Therapeutics Taskforce members to consider his recommendations. No further meetings are currently scheduled. The list below outlines the current membership of the panel:

- Professor James Palmer, National Medical Director Specialised Services, NHS England (chair);

- Dr Vin Diwakar, Regional Medical Director, NHS England (London region) and Medical Director of Secondary Care and Transformation;

- Dr Nikki Kanani, Medical Director of Primary Care for NHS England;

- Dr James Coulson, Consultant Physician, Clinical Pharmacologist and Toxicologist and Clinical Director of the All-Wales Therapeutics and Toxicology Centre;

- Professor Thomas Evans, Institute of Infection, Immunity and Inflammation, University of Glasgow;

- Dr Mark Cross Deputy Medical Director Risk and Governance, Belfast Health and Social Care Trust;

- Dr Matthew Boulter, Senior Clinical Adviser, UK Health Security Agency;

- Dr Nevila Kallfa, Adviser in Public Health Medicine, UK Health Security Agency; and

- Professor Jonathan Benger, Chief Medical Officer, NHS Digital, Professor of Emergency Care, Consultant in Emergency Medicine, University Hospitals Bristol and Weston.